Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03009747
Other study ID # BaS-1611
Secondary ID
Status Not yet recruiting
Phase N/A
First received January 2, 2017
Last updated January 2, 2017
Start date January 2017
Est. completion date December 2019

Study information

Verified date January 2017
Source Peking University People's Hospital
Contact Fan Liu, M.D.
Phone +86-188-1159-0087
Email liufan_md@126.com
Is FDA regulated No
Health authority China: Beijing Municipal Science and Technology CommissionChina: Ethics Committee
Study type Observational

Clinical Trial Summary

This research plans to collect rectal cancer patients after sphincter-preserving surgery from 14 institutions in China mainland, observe the incidence and risk factors about bowel dysfunction after operation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 460
Est. completion date December 2019
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age = 18 years

2. Adenocarcinoma confirmed by pathology

3. Distance from the lowest margin of tumor to the anal verge is = 12cm, confirmed by hard sigmoidoscope.

4. The tumor is estimated to be resectable and confirmed by multidisciplinary team (MDT).

5. The operation is estimated to be sphincter-preserving.

6. The Eastern Cooperative Oncology Group(ECOG) performance status score of patient is = 2.

7. The estimated life time is not less than one year.

8. The patient agree to sign the informed consent.

Exclusion Criteria:

1. The patient refuse to follow research plan.

2. Emergency case

3. Pregnant and lactating female patient

4. The patient did not accept radical resection.

5. The patient did not accept first stage resection and anastomosis.

6. The patient has experienced anal-rectal surgery.

7. The patient has experienced left colon surgery.

8. The patient suffered long-existing bowel dysfunction before rectal cancer diagnosis.

9. The patient was diagnosed with cognitive or communicative obstacles.

10. The patient was diagnosed with serious repeated infection or other concomitance diseases.

11. The patient has participated other medical research which may affect his/her bowel function.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Locations

Country Name City State
n/a

Sponsors (14)

Lead Sponsor Collaborator
Peking University People's Hospital Beijing Cancer Hospital, Beijing Friendship Hospital, Changshu NO.1 People's Hospital, China-Japan Friendship Hospital, First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Hebei Medical University Fourth Hospital, Peking University International Hospital, Qilu Hospital of Shandong university in Qingdao, The Affiliated Hospital of the Chinese Academy of Military Medical Sciences, The First Affiliated Hospital of Anhui Medical University, the first affiliated hospital of Jiamusi university, Xiangya Hospital of Central South University

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of bowel dysfunction after sphincter-preserving surgery one year Yes
Primary Risk factors of bowel dysfunction after sphincter-preserving surgery one year Yes
Secondary Incidence of each symptoms of bowel dysfunction one year Yes
Secondary Prognosis of bowel dysfunction after sphincter-preserving surgery one year Yes
Secondary Incidence of bowel dysfunction after sphincter-preserving surgery comparing incidences between high and low anastomsis site one year Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A